Compass Therapeutics released additional results from its Companion-002 phase II/III study of tovecimig in combination with paclitaxel in second-line biliary tract cancer. The new update included weaker-than-expected overall survival outcomes after investors focused on earlier efficacy signals. While the trial met a key secondary endpoint of progression-free survival, the company’s overall survival findings were described as failing to extend survival compared with chemotherapy in the trial’s intent-to-treat population, with additional analyses tied to crossover patients. Compass said it plans to meet with the U.S. FDA to discuss next steps for a potential BLA. The post-data reaction highlights investor sensitivity to survival endpoints as well as the challenge of translating response dynamics into definitive clinical benefit.